Gillette North Atlantic toiletries sales advance 9% in 1996.
This article was originally published in The Rose Sheet
Executive SummaryGILLETTE NORTH ATLANTIC TOILETRIES SALES UP 9% IN 1996, with profits advancing 10% for the year, the company reported during a Jan. 31 teleconference with securities analysts. In the fourth quarter, toiletries revenue for the North Atlantic Group (U.S., Canada and Western Europe) was also up about 10%. Profits for the quarter, however, "experienced a slight decline" due to "some unfavorable" product mix and promotional spending tied to the launch of the company's new Clear Stick antiperspirant and deodorant formulas for the Gillette Series and Right Guard brands
You may also be interested in...
The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.
Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug; FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.
FerGene bladder cancer therapy achieved a complete response in more than half of patients in its pivotal trial. The joint venture now looks to commercialization and potential expansion of indications.